Developing T-Cell Adaptive Vaccines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen-infected cells.
Introducing Emergex Vaccines
Emergex Vaccines is a clinical-stage, privately held biotechnology company headquartered near Oxford, UK, with R&D facilities in Milton Park, UK and an operating subsidiary in Doylestown, Pennsylvania, USA. Emergex Vaccines is focussed on developing a range of 100% synthetic CD8+ T cell Adaptive Vaccines that harness the body’s natural cellular immune response to destroy pathogen-infected cells and to provide immune protection for some of the world’s most impactful diseases.
We work on addressing some of the world’s most immediate health threats (including viral diseases such as Dengue Fever, COVID-19, Zika, Ebola and pandemic Influenza, as well as serious intracellular bacterial infections) and have a growing pipeline of vaccine candidates.
Our Vision:
To positively impact global human health though the development of next generation vaccines for some of the world’s most immediate health threats.
Latest press releases
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch